Skip to main content
. 2019 Nov 30;8(1):22–26. doi: 10.1016/j.prnil.2019.11.002

Table 1.

Patient characteristics (n = 178).

variable
Median age, years (range) 72 (46-91)
PSA at diagnosis, median (range) 164 (3.2-8740)
Biopsy Gleason score, n (%)
 ≤6 5 (2.8)
 7 29 (16.2)
 ≥8 129 (72.4)
 not available 15 (8.4)
cT stage, n (%)
 T1c 1 (0.5)
 T2a 4 (2.2)
 T2b 5 (2.8)
 T2c 1 (0.5)
 T3a 64 (35.9)
 T3b 43 (24.1)
 T4 52 (29.2)
 not available 8 (4.4)
cN stage
 N0 59 (33.1)
 N1 116 (65.1)
 not available 3 (1.6)
cM stage
 M0 19 (10.6)
 M1 157 (88.2)
 not available 2 (1.1)
Median testosterone, ng/dl (range) 400 (37-1042)
Median BMI, kg/m2 (range) 22.5 (14.5-31.1)
Median visceral fat, % (range) 29.4 (2.1-57.6)
Median V/S ratio, ratio (range) 1.16 (0.34-19.6)
Psoas muscle ratio, ratio (range) 1.95 (0.71-3.64)
hormonal therapy
 Castration 11 (6.2)
 Combined androgen blockage 167 (93.8)

Abbreviations: BMI, body mass index; PSA, prostate-specific antigen; V/S ratio, Visceral fat/subcutaneous fat ratio.

Psoas muscle ratio: Psoas muscle/height (cm3/cm).